Pathwork(美国)

Pathwork Diagnostics

美国PathworkDiagnosticswww.pathworkdx.comPathworkDiagnostics公司是一家从事肿瘤疾病分子诊断技术研发的企业，该公司宣布在一轮融资中获得来自Abingworth总额为2000万美元的投资。据悉，在募资消息宣布前不久，PathworkDiagnostics公司已经得到了食品和药物管理局（FDA）关于对一些不确定病原型肿瘤进行组织病原测试的许可，这些 不确定病原肿瘤包括那些低分化，未分化和转移性肿瘤。PathworkDiagnostics,Inc.,isaprivatelyheldcompanyinRedwoodCity,CA,thatdevelopsandcommercializesinnovative,high-valuemoleculardiagnosticsforoncology.Thecompany’sPathwork®TissueofOriginTestisamicroarray-basedgeneexpressiontestthataidsinidentifyingchallengingtumors,includingpoorlydifferentiated,undifferentiated,andmetastaticcancers.ItistheonlyFDA-clearedandMedicare-coveredmoleculartestofitskind.ThecompanyprovidestheTissueofOriginTestthroughitsCLIA-certified,CAP-accreditedlaboratory.IntheU.S.,approximately150,000newlydiagnosedcancerpatientsmayhaveatumorthatismetastatic,undifferentiated,orpoorlydifferentiated,andoftendifficultto